Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes (Q37894694)

24 August 2017

1 reference

title

Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes (English)

1 reference

24 August 2017

carbapenem antibiotic

0 references

0 references

3

Patrice Nordmann

1 reference

24 August 2017

1

Matthew E Falagas

1 reference

24 August 2017

Drosos E Karageorgopoulos

series ordinal

2

1 reference

PubMed ID

21707312

24 August 2017

language of work or name

1 reference

1 June 2011

1 reference

24 August 2017

14

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

24 August 2017

6

1 reference

24 August 2017

653-666

1 reference

24 August 2017

6

1 reference

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

24 August 2017

1 reference

The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria

21 January 2018

1 reference

Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India

21 January 2018

1 reference

Does broad-spectrum beta-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria?

21 January 2018

1 reference

Worldwide diversity of Klebsiella pneumoniae that produce beta-lactamase blaKPC-2 gene

21 January 2018

1 reference

Interspecies spread of Klebsiella pneumoniae carbapenemase gene in a single patient

21 January 2018

1 reference

Metallo-beta-lactamases: the quiet before the storm?

21 January 2018

1 reference

Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan

21 January 2018

1 reference

First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States.

21 January 2018

1 reference

Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections

21 January 2018

1 reference

The ongoing challenge of acquired carbapenemases: a hospital outbreak of Klebsiella pneumoniae simultaneously producing VIM-1 and KPC-2.

21 January 2018

1 reference

Extremely drug-resistant Citrobacter freundii isolate producing NDM-1 and other carbapenemases identified in a patient returning from India

21 January 2018

1 reference

Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey

21 January 2018

1 reference

Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006-2007.

21 January 2018

1 reference

Spread of OXA-48-encoding plasmid in Turkey and beyond

21 January 2018

1 reference

Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France

21 January 2018

1 reference

Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey.

21 January 2018

1 reference

Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates

21 January 2018

1 reference

Characteristics of meropenem heteroresistance in Klebsiella pneumoniae carbapenemase (KPC)-producing clinical isolates of K. pneumoniae

21 January 2018

1 reference

Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae

21 January 2018

1 reference

Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae

21 January 2018

1 reference

Carbapenem Heteroresistance in VIM-1-producing Klebsiella pneumoniae isolates belonging to the same clone: consequences for routine susceptibility testing

21 January 2018

1 reference

Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem

21 January 2018

1 reference

Infections with VIM-1 metallo-{beta}-lactamase-producing enterobacter cloacae and their correlation with clinical outcome

21 January 2018

1 reference

Fatal cross infection by carbapenem-resistant Klebsiella in two liver transplant recipients

21 January 2018

1 reference

Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection

21 January 2018

1 reference

Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model

21 January 2018

1 reference

Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies

21 January 2018

1 reference

In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae

21 January 2018

1 reference

Adjustment of dosing of antimicrobial agents for bodyweight in adults.

21 January 2018

1 reference

Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic.

21 January 2018

1 reference

Toxicity of polymyxins: a systematic review of the evidence from old and recent studies

21 January 2018

1 reference

Resistance to polymyxins: Mechanisms, frequency and treatment options

21 January 2018

1 reference

Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study

21 January 2018

1 reference

Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary.

21 January 2018

1 reference

Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study

21 January 2018

1 reference

Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients

21 January 2018

1 reference

Orally administered colistin leads to colistin-resistant intestinal flora and fails to prevent faecal colonisation with extended-spectrum β-lactamase-producing enterobacteria in hospitalised newborns.

21 January 2018

1 reference

Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature

21 January 2018

1 reference

Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection

21 January 2018

1 reference

Polymyxin-resistant clinical isolates of Escherichia coli

21 January 2018

1 reference

Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii

21 January 2018

1 reference

In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae

21 January 2018

1 reference

Comparative evaluation of the VITEK 2, disk diffusion, etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains

21 January 2018

1 reference

Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation.

21 January 2018

1 reference

Regulation of polymyxin resistance and adaptation to low-Mg2+ environments

21 January 2018

1 reference

Adaptive resistance to cationic compounds in Pseudomonas aeruginosa.

21 January 2018

1 reference

Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides

21 January 2018

1 reference

Capsule polysaccharide is a bacterial decoy for antimicrobial peptides.

21 January 2018

1 reference

Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis

21 January 2018

1 reference

Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.

21 January 2018

1 reference

Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.

21 January 2018

1 reference

Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use.

21 January 2018

1 reference

Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens

21 January 2018

1 reference

Use of international units when dosing colistin will help decrease confusion related to various formulations of the drug around the world

21 January 2018

1 reference

Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection

21 January 2018

1 reference

An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes

21 January 2018

1 reference

Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek University Hospital

21 January 2018

1 reference

Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study.

21 January 2018

1 reference

Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria

21 January 2018

1 reference

Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae

21 January 2018

1 reference

Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin

21 January 2018

1 reference

Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies

21 January 2018

1 reference

Correlation of the expression of acrB and the regulatory genes marA, soxS and ramA with antimicrobial resistance in clinical isolates of Klebsiella pneumoniae endemic to New York City

21 January 2018

1 reference

Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline

21 January 2018

1 reference

In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates

21 January 2018

1 reference

Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials

21 January 2018

1 reference

Tigecycline and bacteremia--the dangers of post hoc analysis of pooled data

21 January 2018

1 reference

Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes.

21 January 2018

1 reference

Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia

21 January 2018

1 reference

Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens

21 January 2018

1 reference

Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline

21 January 2018

1 reference

Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates

21 January 2018

1 reference

Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin.

21 January 2018

1 reference

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients

21 January 2018

1 reference

Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa

21 January 2018

1 reference

Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review.

21 January 2018

1 reference

In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin

21 January 2018

1 reference

CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin.

21 January 2018

1 reference

Fosfomycin: use beyond urinary tract and gastrointestinal infections

21 January 2018

1 reference

Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections

21 January 2018

1 reference

Biological costs and mechanisms of fosfomycin resistance in Escherichia coli

21 January 2018

1 reference

Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance.

21 January 2018

1 reference

In vitro activity of fosfomycin against Gram-negative urinary pathogens and the biological cost of fosfomycin resistance

21 January 2018

1 reference

Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation

21 January 2018

1 reference

Regional dissemination of KPC-producing Klebsiella pneumoniae

21 January 2018

1 reference

New Delhi metallo-beta-lactamase from traveler returning to Canada

21 January 2018

1 reference

An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project

21 January 2018

1 reference

The evolution of the sensitivity to fosfomycin over the past two years.

21 January 2018

1 reference

Effect of Fosfomycin on the Fecal Microflora of Man

21 January 2018

1 reference

Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial.

21 January 2018

1 reference

Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.

21 January 2018

1 reference

In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae

21 January 2018

1 reference

Carbapenem-resistant Klebsiella pneumoniae endocarditis in a young adult. Successful treatment with gentamicin and colistin.

21 January 2018

1 reference

Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents

21 January 2018

1 reference

Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates?

21 January 2018

1 reference

In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase

21 January 2018

1 reference

In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development

21 January 2018

1 reference

Protective effect of fosfomycin on gentamicin-induced lipid peroxidation of rat renal tissue

21 January 2018

1 reference

Natural history of colonization with gram-negative multidrug-resistant organisms among hospitalized patients

21 January 2018

1 reference

Recurrent healthcare-associated community-onset infections due to Klebsiella pneumoniae producing VIM-1 metallo-beta-lactamase

21 January 2018

1 reference

Global spread of New Delhi metallo-β-lactamase 1.

21 January 2018

1 reference

Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community

21 January 2018

1 reference

Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia

21 January 2018

1 reference

The antibiotic development pipeline for multidrug‐resistant gram‐negative bacilli: current and future landscapes

21 January 2018

1 reference

Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates

21 January 2018

1 reference

New β-lactam antibiotics and β-lactamase inhibitors

21 January 2018

1 reference

Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae

21 January 2018

1 reference

Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae

21 January 2018

1 reference

In vitro activity of penem-1 in combination with beta-lactams against blaKPC-possessing Klebsiella pneumoniae isolates

21 January 2018

1 reference

Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms

21 January 2018

1 reference

Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampicin and clarithromycin

21 January 2018

1 reference

Liposomes as delivery systems for antibiotics

21 January 2018

1 reference

Aerosol delivery of antimicrobial agents during mechanical ventilation: current practice and perspectives

21 January 2018

1 reference

Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control.

21 January 2018

1 reference

Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii

21 January 2018

1 reference

Efficacy of carbapenems against a metallo- -lactamase-producing Escherichia coli clinical isolate in a rabbit intra-abdominal abscess model

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FMB.11.49

1 reference

24 August 2017

1 reference

PubMed ID

21707312